Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 11, 2020 06:03 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors

~ No Clinical Safety or Efficacy Issues Identified, and No Requirement for Further Clinical Data ~ ~ FDA Pre-Approval Inspection has Identified Deficiencies with the Facility of the Drug Product...
August 05, 2020 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update

~ FDA Set a PDUFA Target Action Date for PEDMARKTM of August 10, 2020 ~~ Strong Financial Position with $38.7 million in cash and no debt ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2020 (GLOBE...
June 26, 2020 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility

RESEARCH TRIANGLE PARK, N.C., June 26, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a...
June 22, 2020 18:03 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 22, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy...
May 14, 2020 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Business Update

~ FDA Set a PDUFA Target Action Date for PEDMARKTM of August 10, 2020 ~~ Marketing Authorization Application (MAA) Validated by the EMA in February 2020 ~~ Strengthened its Financial Position Through...
May 08, 2020 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Announces Exercise and Closing of Underwriters’ Option to Purchase Additional Shares

RESEARCH TRIANGLE PARK, N.C., May 08, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC) (TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...
May 05, 2020 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Announces Closing of Public Offering

RESEARCH TRIANGLE PARK, N.C., May 05, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC) (TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...
April 30, 2020 09:16 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Announces Pricing of Public Offering

RESEARCH TRIANGLE PARK, N.C., April 30, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...
April 29, 2020 16:01 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Announces Proposed Public Offering of Common Shares

RESEARCH TRIANGLE PARK, N.C., April 29, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a...
April 13, 2020 07:08 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of New Drug Application for PEDMARK™

~ Potential for PEDMARK to be the First Product for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ FDA Grants Priority Review and Sets a Prescription Drug User Fee Act (PDUFA)...